Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo

Y. Sakaguchi, Y. Maehara, Y. Emi, S. Kohnoe, K. Sugimachi

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The cytotoxicity of adriamyin (ADM) combined with hyperthermia (Hyp) and/or dipyridamole (DP) was investigated using B16 melanoma cells in vitro and in vivo. When ADM was combined with Hyp at 43 °C or DP in a dose of 5 u.V/ or with both, drug cytotoxicity enhanced the inhibition of colony formation and cell growth, and the effect was maximal when Hyp and DP were combined. Incubation with DP alone for 24 h. following ADM exposure, enhanced the toxicity even further (p < 0.01). Measurement of intracellular levels of ADM in the B16 melanoma cells showed that Hyp and DP increased accumulation of ADM, and that DP, but not Hyp. significantly suppressed the ADM excretion (p < 0.05). Growth of B16 melanoma implanted into subcutaneous tissue of the foot of C57BL mice was inhibited to a greater extent by the combination treatment of ADM and DP, ADM and Hyp, and also that of ADM, Hyp and DP, compared to the findings in cases of ADM or Hyp alone. As this trimodality treatment is effective both in vitro and in vivo, further study on possible clinical advantage is warranted.

Original languageEnglish
Pages (from-to)249-256
Number of pages8
JournalEuropean Surgical Research
Volume24
Issue number4
DOIs
Publication statusPublished - Jan 1 1992

Fingerprint

Dipyridamole
Doxorubicin
Fever
Experimental Melanomas
In Vitro Techniques
Subcutaneous Tissue
Growth
Inbred C57BL Mouse
Foot
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo. / Sakaguchi, Y.; Maehara, Y.; Emi, Y.; Kohnoe, S.; Sugimachi, K.

In: European Surgical Research, Vol. 24, No. 4, 01.01.1992, p. 249-256.

Research output: Contribution to journalArticle

Sakaguchi, Y. ; Maehara, Y. ; Emi, Y. ; Kohnoe, S. ; Sugimachi, K. / Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo. In: European Surgical Research. 1992 ; Vol. 24, No. 4. pp. 249-256.
@article{40c73211c7244fb6ab422e814813b53e,
title = "Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo",
abstract = "The cytotoxicity of adriamyin (ADM) combined with hyperthermia (Hyp) and/or dipyridamole (DP) was investigated using B16 melanoma cells in vitro and in vivo. When ADM was combined with Hyp at 43 °C or DP in a dose of 5 u.V/ or with both, drug cytotoxicity enhanced the inhibition of colony formation and cell growth, and the effect was maximal when Hyp and DP were combined. Incubation with DP alone for 24 h. following ADM exposure, enhanced the toxicity even further (p < 0.01). Measurement of intracellular levels of ADM in the B16 melanoma cells showed that Hyp and DP increased accumulation of ADM, and that DP, but not Hyp. significantly suppressed the ADM excretion (p < 0.05). Growth of B16 melanoma implanted into subcutaneous tissue of the foot of C57BL mice was inhibited to a greater extent by the combination treatment of ADM and DP, ADM and Hyp, and also that of ADM, Hyp and DP, compared to the findings in cases of ADM or Hyp alone. As this trimodality treatment is effective both in vitro and in vivo, further study on possible clinical advantage is warranted.",
author = "Y. Sakaguchi and Y. Maehara and Y. Emi and S. Kohnoe and K. Sugimachi",
year = "1992",
month = "1",
day = "1",
doi = "10.1159/000129213",
language = "English",
volume = "24",
pages = "249--256",
journal = "European Surgical Research",
issn = "0014-312X",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Adriamycin combined with hyperthermia and dipyridamole is cytotoxic both in vitro and in vivo

AU - Sakaguchi, Y.

AU - Maehara, Y.

AU - Emi, Y.

AU - Kohnoe, S.

AU - Sugimachi, K.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The cytotoxicity of adriamyin (ADM) combined with hyperthermia (Hyp) and/or dipyridamole (DP) was investigated using B16 melanoma cells in vitro and in vivo. When ADM was combined with Hyp at 43 °C or DP in a dose of 5 u.V/ or with both, drug cytotoxicity enhanced the inhibition of colony formation and cell growth, and the effect was maximal when Hyp and DP were combined. Incubation with DP alone for 24 h. following ADM exposure, enhanced the toxicity even further (p < 0.01). Measurement of intracellular levels of ADM in the B16 melanoma cells showed that Hyp and DP increased accumulation of ADM, and that DP, but not Hyp. significantly suppressed the ADM excretion (p < 0.05). Growth of B16 melanoma implanted into subcutaneous tissue of the foot of C57BL mice was inhibited to a greater extent by the combination treatment of ADM and DP, ADM and Hyp, and also that of ADM, Hyp and DP, compared to the findings in cases of ADM or Hyp alone. As this trimodality treatment is effective both in vitro and in vivo, further study on possible clinical advantage is warranted.

AB - The cytotoxicity of adriamyin (ADM) combined with hyperthermia (Hyp) and/or dipyridamole (DP) was investigated using B16 melanoma cells in vitro and in vivo. When ADM was combined with Hyp at 43 °C or DP in a dose of 5 u.V/ or with both, drug cytotoxicity enhanced the inhibition of colony formation and cell growth, and the effect was maximal when Hyp and DP were combined. Incubation with DP alone for 24 h. following ADM exposure, enhanced the toxicity even further (p < 0.01). Measurement of intracellular levels of ADM in the B16 melanoma cells showed that Hyp and DP increased accumulation of ADM, and that DP, but not Hyp. significantly suppressed the ADM excretion (p < 0.05). Growth of B16 melanoma implanted into subcutaneous tissue of the foot of C57BL mice was inhibited to a greater extent by the combination treatment of ADM and DP, ADM and Hyp, and also that of ADM, Hyp and DP, compared to the findings in cases of ADM or Hyp alone. As this trimodality treatment is effective both in vitro and in vivo, further study on possible clinical advantage is warranted.

UR - http://www.scopus.com/inward/record.url?scp=0026689533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026689533&partnerID=8YFLogxK

U2 - 10.1159/000129213

DO - 10.1159/000129213

M3 - Article

C2 - 1505600

AN - SCOPUS:0026689533

VL - 24

SP - 249

EP - 256

JO - European Surgical Research

JF - European Surgical Research

SN - 0014-312X

IS - 4

ER -